Alzheimer's Disease New Molecular Approach

Phfr, Inc.

Alzheimer's Disease

New Molecular Approach

Home Acetyl-l-carnitine (ALCAR) is an important naturally occurring molecule that can help ameliorate the membrane and energy changes seen in AD.  ALCAR has been repeatedly demonstrated to have few and only minimal side effects.  Mild gastrointestinal symptoms may occur in some individuals, these include nausea, vomiting, abdominal cramps, and diarrhea.

ALCAR contains carnitine and acetyl moieties, both of which have neurobiological properties.  ALCAR is reported to affect brain energy and phospholipid metabolism, to interact with cell membranes, proteins, and enzymes, and to have nerve growth factor-like properties (for review see Pettegrew et al., 2000b).

Pettegrew et al., (1995b) conducted a 31P-MRS double-blind, placebo-controlled study of ALCAR in 12 patients with probable AD.  Cognitive test scores of the placebo group deteriorated significantly at 6 and 12 months whereas cognitive scores of the ALCAR treated group did not significantly change demonstrating ALCAR slowed the clinical progression of AD.  Subjects receiving ALCAR demonstrated improvement in brain measures of membrane phospholipid and high-energy phosphate metabolism linking improvement in cognition with improvement in these metabolic pathways.  This was the first and still the only report in the literature that demonstrates a therapeutic agent (ALCAR) can alter both the clinical course and brain molecular changes in AD.

Our Goal
Contact Us
Corporate Officers
Role of Nerve Cell Membranes
Alzheimer's disease
  Molecular Problem
Problem with Current Drugs
New Molecular Approach
Preclinical Biomarkers
Patent Application
Relevant Articles
Depressive Disorders
Chronic Alcoholism
Cryopreservation
Plant Nutraceuticals

Parkinson's Disease

Developmental Disorders

 

 

| Home | Our Goal | Contact Us | Corporate Officers | Role of Nerve Cell Membranes |
        | Alzheimer's disease | Depressive Disorders | Chronic Alcoholism | Cryopreservation |

Copyright 2005 Phfr, Inc.
All rights reserved